Expand PFE Menu
PFE MENU

PFE Latest Press Releases

-- September 4, 2024 --

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 Globe Newswire 8:30 AM

-- September 3, 2024 --

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate Globe Newswire 1:00 AM

-- August 28, 2024 --

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- August 27, 2024 --

Pfizer Launches PfizerForAll , a Digital Platform that Helps Simplify Access to Healthcare Business Wire 6:45 AM

-- August 22, 2024 --

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine Globe Newswire 2:15 PM
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine Business Wire 2:15 PM

-- August 16, 2024 --

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Globe Newswire 6:45 AM
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Business Wire 6:45 AM

-- August 12, 2024 --

Pfizer Announces Top-Line Results of ABRYSVO for RSV in Immunocompromised Adults Business Wire 6:45 AM

-- August 6, 2024 --

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 Globe Newswire 8:30 AM

-- July 30, 2024 --

Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance Business Wire 6:45 AM

-- July 25, 2024 --

European Commission Approves Pfizer's DURVEQTIX (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B Business Wire 10:48 AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected Globe Newswire 8:30 AM

-- July 24, 2024 --

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate Business Wire 6:45 AM

-- July 23, 2024 --

ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 Business Wire 4:06 AM

-- July 17, 2024 --

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion Globe Newswire 4:00 PM
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts Business Wire 8:00 AM

-- July 15, 2024 --

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024 Business Wire 8:32 AM

-- July 11, 2024 --

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron Business Wire 6:45 AM

-- July 9, 2024 --

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development Business Wire 6:45 AM

-- July 1, 2024 --

Cyrus Taraporevala Elected to Pfizer's Board of Directors Business Wire 6:45 AM

-- June 27, 2024 --

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union Business Wire 10:30 AM
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union Globe Newswire 10:30 AM

-- June 26, 2024 --

Pfizer Declares Third-Quarter 2024 Dividend Business Wire 4:30 PM

-- June 18, 2024 --

Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts Business Wire 10:00 AM

-- June 14, 2024 --

ELREXFIO Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma Business Wire 3:00 AM

-- June 12, 2024 --

Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy Business Wire 4:30 PM

-- June 5, 2024 --

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 Globe Newswire 4:05 PM

-- June 3, 2024 --

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- June 1, 2024 --

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma Business Wire 8:00 AM
Pfizer's ADCETRIS Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire 8:00 AM

-- May 31, 2024 --

Pfizer's LORBRENA CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression Business Wire 8:00 AM

-- May 24, 2024 --

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 Globe Newswire 8:45 AM

-- May 16, 2024 --

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) Globe Newswire 6:00 AM

-- May 13, 2024 --

Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting PRNewswire 8:00 AM

-- May 8, 2024 --

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024 Globe Newswire 8:30 AM

-- May 6, 2024 --

Pfizer Announces New Chief Strategy and Innovation Officer Business Wire 6:45 AM

-- May 2, 2024 --

AM Best Affirms Credit Ratings of Blue Whale Re Ltd. Business Wire 3:33 PM

-- May 1, 2024 --

Pfizer Reports First-Quarter 2024 Results Business Wire 6:45 AM

-- April 29, 2024 --

FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer Business Wire 6:40 PM
TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Globe Newswire 6:40 PM
TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Business Wire 6:40 PM
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting Business Wire 6:45 AM

-- April 26, 2024 --

U.S. FDA Approves Pfizer's BEQVEZ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B Business Wire 6:45 AM

-- April 24, 2024 --

Pfizer Declares Second-Quarter 2024 Dividend Business Wire 4:37 PM

-- April 22, 2024 --

European Commission Approves Pfizer's EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options Business Wire 8:08 AM

-- April 11, 2024 --

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 Business Wire 10:00 AM

-- April 9, 2024 --

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease Business Wire 6:45 AM